Ajobiewe JO¹*, Adetuyi Bisayo³, Ajobiewe HF², Akinloye Oyetunde⁷, Patrick Pillah¹, Victoria Pillah⁴, Alau Kenneth⁵, Aisha Salami⁶ and Yashim AN⁷

¹Veritas University, Bwari Abuja, Nigeria
²Bingham University, Karu Nasarawa State of Nigeria, Nigeria
³National Open University, Dutze Study Center, Abuja, Nigeria
⁴Nigerian National University Commission 'NUC', Nigeria
⁵Health System Consults Limited (HSCL), Abuja, Nigeria
⁶United State Department of Defense, Walter Reed Program, Nigeria US Embassy Nig., Nigeria
⁷Baze University, Abuja, Nigeria

*Corresponding Author: Ajobiewe JO, Veritas University, Bwari Abuja, Nigeria.

Received: March 03, 2023; Published: January 26, 2024

Abstract

Hepatitis B virus (HBV) infections is one of the most common cause of maternal morbidity and mortality. Studies on seroprevalence of HBV among pregnant women attending antenatal clinic at Federal Medical Centre, Keffi, Nasarawa state, Nigeria was carried out. A total of 106 serum samples of pregnant women attending the antenatal clinic were obtained and HBV was detected using HBV test kits. Out of 106 serum samples of pregnant women attending the antenatal clinic, the prevalence of HBV infection was 28(26.4%). The prevalence of HBV among the pregnant women was highest among those within the age group 21-25yrs (57.9%) The prevalence of HBV was also high among pregnant women with informal education (37.0%) and farmers (31.6%) as well as the single (51.4%) and those with history of blood transfusion (32.2%) and first trimester of pregnancy (34.4%) respectively. The prevalence of HBV among the pregnant women in relation to socio-demographic factors of the pregnant women were statistically significant (P < 0.05) in agreement with World Health Organization (WHO) findings.

Keywords: World Health Organization (WHO); Prevalence; Pregnant; Women; Hepatitis B virus (HBV) Federal Medical Centre; Keffi; Nasarawa state; Nigeria; Infection

References

1. Adabara NU., et al. “Prevalence of Hepatitis B Virus among Women Attending Antenatal Clinic in the General Hospital, Minna, Niger State”. (2012).
2. Altiparmak E., et al. “Seroprevalence of hepatitis B e antigen (HBe antigen) and B core antibodies (IgG anti-HBcore and IgM anti-HBcore) among hepatitis B”. BMC Research Notes (2012).
3. American Academy of Family Physicians (AAFP). “Clinical preventive service recommendation: hepatitis”. AAFP website (2019).
4. Aseb Arba Kinfe. “Co-contributor of prevalence hepatitis B viruses and associated factors among pregnant women attending ante natal clinic public hospitals of wolaita zone, South Ethiopia”. (2020).
5. Bancha B., et al. “Contributor to prevalence hepatitis B viruses and associated factors among pregnant women attending ante natal clinic public hospital, South Ethiopia”. (2021).
6. Berinyuy B Eustace., et al. “Prevalence of Hepatitis B Virus in Nigeria”. Journal of Public Health and Epidemiology (2019).
7. Centers for Disease Control and Prevention (CDC). Hepatitis B information. CDC website (2019).
8. DahieHA and Heyle AA. “Prevalence of Hepatitis B and its associated factors among pregnant women in Mogadishu, Somalia”. Archives of Business Research11 (2017).
9. IM Ifeorah., et al. “Seroprevalence of hepatitis B and delta viruses among HIV-infected population attending anti-retroviral clinic in selected health facilities in Abuja, Nigeria”. Journal of Immunoassay and Immunochemistry6 (2017): 608-619.
10. Ibrahim Adamu Yakasai., et al. Department of obstertrics and Gynaecology, Bayero University / Aminu Kano Teaching Hospital, Kano, Nigeria (2017).
11. Kebede KM., et al. “Hepatitis B virus infection among pregnant women in Ethiopia: a systematic review and meta-analysis of prevalence studies”. British Medical journal of Infectious Disease 18.1 (2018): 322.
12. Mustapha G U., et al. “Seroprevalence of hepatitis B virus among antenatal clinic attendees in Gamawa Local Government Area, Bauchi State, Nigeria”. BMC Infectious Diseases1 (2020).
13. Henderson J T., et al. “Screening for hepatitis B infection in pregnant women: updated evidence report and systematic review for the US Preventive Services Task Force”. JAMA (2020).
14. Henderson JT., et al. “Screening for hepatitis B virus infection in pregnant women: an updated systematic review for the U.S. preventive services task force”. Evidence Synthesis No. 179. AHRQ Publication No. 19-05248-EF-1, Agency for Healthcare Research and Quality, Rockville, MD, (2019).
15. Hadden J., et al. “All-atom molecular dynamics of the HBV capsid reveals insights into biological function and cryo-EM resolution limits”. Elife (2018).
16. Mckenzie Samuel. “Hepatitis B Structure: Capsid Flexibility and Function”. News-Medical (2019).
17. National Institute of Diabetes and Digestive and Kidney Diseases. Autoimmune Hepatitis (2018).
18. Cetin S., et al. “Seroprevalence of hepatitis B surface antigen and associated risk factors among pregnant women”. Journal of Infection in Developing Countries10 (2018): 904–909.
19. USPSTF (US Preventive Services Task Force). USPSTF A and B Recommendations (2018).
20. WHO Executive Board. Viral hepatitis. Report by the Secretariat. EB126/15, 12 November (2009).
21. WHO Global Hepatitis Report 2017. World Health Organization. Guidelines (2019).
22. “Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection”. Geneva (2015).
23. “Hepatitis B and breastfeeding” (1996).
24. World Hepatitis Summit 2022. Global Hepatitis programme. WHO@ world hepatitis summit (2022).

Citation

Citation: Ajobiewe JO., et al. “Prevalence of Hepatitis B Among Pregnant Women Attending Ante-Natal Clinic in Federal Medical Centre Keffi, Nasarawa State, Nigeria".Acta Scientific Microbiology 7.2 (2024): 118-132.

Copyright

Copyright: © 2024 Ajobiewe JO., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.